TUESDAY, Oct. 9, 2018 (HealthDay News) -- Lorcaserin reduces the risk for diabetes in obese or overweight patients with prediabetes or without diabetes and reduces hemoglobin A1c (HbA1c) among those with diabetes, according to a study published online Oct. 4 in The Lancet. The research was published to coincide with the annual meeting of the European Association for the Study of Diabetes held from Oct. 1 to 5 in Berlin.
Erin A. Bohula, M.D., from the Brigham and Women's Hospital in Boston, and colleagues randomized 12,000 overweight or obese patients with or at high risk for atherosclerotic vascular disease to receive either lorcaserin or matching placebo.
At baseline, 56.8, 33.3, and 9.9 percent of patients had diabetes, prediabetes, and normoglycemia, respectively. The researchers found that at one year, patients treated with lorcaserin had a net weight loss beyond placebo of 2.6, 2.8, and 3.3 kg for those with diabetes, prediabetes, and normoglycemia, respectively. Lorcaserin reduced the risk for incident diabetes by 19 and 23 percent in patients with prediabetes and those without diabetes, respectively (hazard ratios, 0.81 and 0.77, respectively). In patients with prediabetes, lorcaserin resulted in a nonsignificant increase in the rate of achievement of normoglycemia. For patients with diabetes, lorcaserin resulted in a reduction of 0.33 percent in HbA1c at one year compared with placebo.
"Lorcaserin decreases risk for incident diabetes, induces remission of hyperglycemia, and reduces the risk of microvascular complications in obese and overweight patients, supporting the role of lorcaserin as an adjunct to lifestyle modification for chronic management of weight and metabolic health," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Eisai, which manufactures lorcaserin and funded the study.